Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast

Detalhes bibliográficos
Autor(a) principal: Barbosa-Lima, Ricardo
Data de Publicação: 2020
Outros Autores: Kameo, Simone Yuriko, Amorim, Bruno Ferreira, Ramos, Maria Júlia Oliveira, Costa, Jéssica dos Santos, Marinho, Pabliane Matias Lordelo, Sawada, Namie Okino, Moura Silva, Glebson
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Ciências em Saúde
Texto Completo: https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040
Resumo: Objective: To describe the occurrence of oral mucositis (OM) in women undergoing cancer treatment for breast cancer (BC). Methods: This is a retrospective, quantitative, and analytical study in medical records of women diagnosed with BC in an oncology service. Clinical data were collected regarding the occurrence and severity of OM according to the World Health Organization criteria and the cancer treatment experienced by the participants.  Results: 196 women were included. Of these, 97 (49.5%) developed OM, 43.4% of which were grade 1 or 2 (low or moderate). The occurrence was higher in white women (OR 1.93; 95% CI 1.04 - 3.57; p = 0.035), with metastatic breast cancer (OR 5.46; 95% CI 1.79 - 16.64; p = 0.002) and who experienced taxane agents at some point during chemotherapy (OR 2.26; 95% CI 1.12 - 4.56; p = 0.02). The mean severity of OM in the entire sample was 0.8 ± 1.0, and in the affected women was 1.7 ± 0.7. The difference in the severity of OM by the variables was observed only among women with grade 2 and grade 3 fatigue (p = 0.03). Conclusions: OM is a common mucocutaneous toxicity in women with BC. Despite the low severity observed, care for women with BC undergoing cancer treatment must consider the possible risks and complications associated with OM, adopting strategies to prevent, monitor, and treat them.
id RCS_a23e635bd9f41b99dd6591a78c7da905
oai_identifier_str oai:ojs.portalrcs.hcitajuba.org.br:article/1040
network_acronym_str RCS
network_name_str Revista Ciências em Saúde
repository_id_str
spelling Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian NortheastOcorrência de mucosite oral em mulheres durante tratamento oncológico de câncer de mama no Nordeste brasileirobreast neoplasmsepidemiologyoral mucositisStomatitisoral mucositisbreast neoplasmepidemiologiamucosite oralneoplasias da mamaestomatitemucosite oralcâncer de mamaObjective: To describe the occurrence of oral mucositis (OM) in women undergoing cancer treatment for breast cancer (BC). Methods: This is a retrospective, quantitative, and analytical study in medical records of women diagnosed with BC in an oncology service. Clinical data were collected regarding the occurrence and severity of OM according to the World Health Organization criteria and the cancer treatment experienced by the participants.  Results: 196 women were included. Of these, 97 (49.5%) developed OM, 43.4% of which were grade 1 or 2 (low or moderate). The occurrence was higher in white women (OR 1.93; 95% CI 1.04 - 3.57; p = 0.035), with metastatic breast cancer (OR 5.46; 95% CI 1.79 - 16.64; p = 0.002) and who experienced taxane agents at some point during chemotherapy (OR 2.26; 95% CI 1.12 - 4.56; p = 0.02). The mean severity of OM in the entire sample was 0.8 ± 1.0, and in the affected women was 1.7 ± 0.7. The difference in the severity of OM by the variables was observed only among women with grade 2 and grade 3 fatigue (p = 0.03). Conclusions: OM is a common mucocutaneous toxicity in women with BC. Despite the low severity observed, care for women with BC undergoing cancer treatment must consider the possible risks and complications associated with OM, adopting strategies to prevent, monitor, and treat them.Objetivo: Descrever a ocorrência de mucosite oral (MO) em mulheres em tratamento oncológico para câncer de mama (CM). Métodos: Trata-se de um estudo retrospectivo, quantitativo e analítico em prontuários de mulheres com diagnóstico de CM em um serviço de oncologia. Dados clínicos foram coletados quanto à ocorrência e gravidade da MO de acordo com os critérios da Organização Mundial da Saúde e o tratamento oncológico vivenciado pelas participantes. Resultados: Foram incluídas 196 mulheres. Destas, 97 (49,5%) desenvolveram MO, sendo 43,4% grau 1 ou 2 (baixo ou moderado). A ocorrência foi maior em mulheres brancas (OR 1,93; IC95% 1,04 – 3,57; p = 0,035), com câncer de mama metastático (OR 5,46; IC95% 1,79 – 16,64; p = 0,002) e que experimentaram agentes taxanos em algum momento da quimioterapia (OR 2,26; IC95% 1,12 – 4,56; p = 0,02). A gravidade média da MO em toda a amostra foi de 0,8 ± 1,0 e nas mulheres afetadas foi de 1,7 ± 0,7. Diferença na gravidade da MO pelas variáveis foi observada apenas entre as mulheres com fadiga grau 2 e grau 3 (p = 0,03). Conclusões: MO é uma toxicidade mucocutânea comum em mulheres com CM. Apesar da baixa gravidade observada, o cuidado à mulher com CM em tratamento oncológico deve considerar os possíveis riscos e complicações associadas à MO, adotando estratégias para prevenir, monitorar e tratá-las.AISI/HCI2020-12-18info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer reviewedAvaliado pelos parestextoinfo:eu-repo/semantics/otherapplication/pdftext/xmltext/htmlhttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/104010.21876/rcshci.v10i4.1040Revista Ciências em Saúde; v. 10 n. 4 (2020): Outubro a Dezembro de 2020; 144-150Health Sciences Journal; Vol 10 No 4 (2020): October to December 2020; 144-1502236-378510.21876/rcshci.v10i4reponame:Revista Ciências em Saúdeinstname:Hospital de Clínicas de Itajubáinstacron:HCIenghttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/626https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/632https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/650Copyright (c) 2020 Revista Ciências em Saúdehttps://creativecommons.org/licenses/by-nc-sa/4.0info:eu-repo/semantics/openAccessBarbosa-Lima, RicardoKameo, Simone YurikoAmorim, Bruno FerreiraRamos, Maria Júlia OliveiraCosta, Jéssica dos SantosMarinho, Pabliane Matias LordeloSawada, Namie OkinoMoura Silva, Glebson2021-01-07T17:10:14Zoai:ojs.portalrcs.hcitajuba.org.br:article/1040Revistahttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zeroPUBhttps://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/oaircs@hcitajuba.org.br||rcsfmit@medicinaitajuba.com.br2236-37852236-3785opendoar:2021-01-07T17:10:14Revista Ciências em Saúde - Hospital de Clínicas de Itajubáfalse
dc.title.none.fl_str_mv Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast
Ocorrência de mucosite oral em mulheres durante tratamento oncológico de câncer de mama no Nordeste brasileiro
title Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast
spellingShingle Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast
Barbosa-Lima, Ricardo
breast neoplasms
epidemiology
oral mucositis
Stomatitis
oral mucositis
breast neoplasm
epidemiologia
mucosite oral
neoplasias da mama
estomatite
mucosite oral
câncer de mama
title_short Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast
title_full Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast
title_fullStr Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast
title_full_unstemmed Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast
title_sort Occurrence of oral mucositis in women during oncological treatment of breast cancer in the Brazilian Northeast
author Barbosa-Lima, Ricardo
author_facet Barbosa-Lima, Ricardo
Kameo, Simone Yuriko
Amorim, Bruno Ferreira
Ramos, Maria Júlia Oliveira
Costa, Jéssica dos Santos
Marinho, Pabliane Matias Lordelo
Sawada, Namie Okino
Moura Silva, Glebson
author_role author
author2 Kameo, Simone Yuriko
Amorim, Bruno Ferreira
Ramos, Maria Júlia Oliveira
Costa, Jéssica dos Santos
Marinho, Pabliane Matias Lordelo
Sawada, Namie Okino
Moura Silva, Glebson
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Barbosa-Lima, Ricardo
Kameo, Simone Yuriko
Amorim, Bruno Ferreira
Ramos, Maria Júlia Oliveira
Costa, Jéssica dos Santos
Marinho, Pabliane Matias Lordelo
Sawada, Namie Okino
Moura Silva, Glebson
dc.subject.por.fl_str_mv breast neoplasms
epidemiology
oral mucositis
Stomatitis
oral mucositis
breast neoplasm
epidemiologia
mucosite oral
neoplasias da mama
estomatite
mucosite oral
câncer de mama
topic breast neoplasms
epidemiology
oral mucositis
Stomatitis
oral mucositis
breast neoplasm
epidemiologia
mucosite oral
neoplasias da mama
estomatite
mucosite oral
câncer de mama
description Objective: To describe the occurrence of oral mucositis (OM) in women undergoing cancer treatment for breast cancer (BC). Methods: This is a retrospective, quantitative, and analytical study in medical records of women diagnosed with BC in an oncology service. Clinical data were collected regarding the occurrence and severity of OM according to the World Health Organization criteria and the cancer treatment experienced by the participants.  Results: 196 women were included. Of these, 97 (49.5%) developed OM, 43.4% of which were grade 1 or 2 (low or moderate). The occurrence was higher in white women (OR 1.93; 95% CI 1.04 - 3.57; p = 0.035), with metastatic breast cancer (OR 5.46; 95% CI 1.79 - 16.64; p = 0.002) and who experienced taxane agents at some point during chemotherapy (OR 2.26; 95% CI 1.12 - 4.56; p = 0.02). The mean severity of OM in the entire sample was 0.8 ± 1.0, and in the affected women was 1.7 ± 0.7. The difference in the severity of OM by the variables was observed only among women with grade 2 and grade 3 fatigue (p = 0.03). Conclusions: OM is a common mucocutaneous toxicity in women with BC. Despite the low severity observed, care for women with BC undergoing cancer treatment must consider the possible risks and complications associated with OM, adopting strategies to prevent, monitor, and treat them.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-18
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer reviewed
Avaliado pelos pares
texto
info:eu-repo/semantics/other
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040
10.21876/rcshci.v10i4.1040
url https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040
identifier_str_mv 10.21876/rcshci.v10i4.1040
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/626
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/632
https://portalrcs.hcitajuba.org.br/index.php/rcsfmit_zero/article/view/1040/650
dc.rights.driver.fl_str_mv Copyright (c) 2020 Revista Ciências em Saúde
https://creativecommons.org/licenses/by-nc-sa/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Revista Ciências em Saúde
https://creativecommons.org/licenses/by-nc-sa/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
text/xml
text/html
dc.publisher.none.fl_str_mv AISI/HCI
publisher.none.fl_str_mv AISI/HCI
dc.source.none.fl_str_mv Revista Ciências em Saúde; v. 10 n. 4 (2020): Outubro a Dezembro de 2020; 144-150
Health Sciences Journal; Vol 10 No 4 (2020): October to December 2020; 144-150
2236-3785
10.21876/rcshci.v10i4
reponame:Revista Ciências em Saúde
instname:Hospital de Clínicas de Itajubá
instacron:HCI
instname_str Hospital de Clínicas de Itajubá
instacron_str HCI
institution HCI
reponame_str Revista Ciências em Saúde
collection Revista Ciências em Saúde
repository.name.fl_str_mv Revista Ciências em Saúde - Hospital de Clínicas de Itajubá
repository.mail.fl_str_mv rcs@hcitajuba.org.br||rcsfmit@medicinaitajuba.com.br
_version_ 1797068962841755648